Wang Miaomiao, Cao Liang, Wang Yinzhong, Huang Hongliang, Tian Xiaoxue, Lei Junqiang
The First Clinical Medical College of Lanzhou University, No.1 Donggang West Road, Lanzhou City, Gansu Province, China.
Department of Radiology, The First Hospital of Lanzhou University, No.1 Donggang West Road, Lanzhou City, 730000, Gansu Province, China.
Clin Transl Oncol. 2024 Aug;26(8):2037-2046. doi: 10.1007/s12094-024-03427-2. Epub 2024 Mar 25.
Studies have suggested that vessels encapsulating tumor clusters (VETC) is a strong predictor of prognosis in patients with hepatocellular carcinoma (HCC).
A systematic search was conducted in PubMed, Embase, Web of Science, and Scopus databases. Overall survival (OS) and tumor efficacy (TE) were two outcome measures used to evaluate the relationship between VETC and HCC prognosis. Hazard ratios (HR) and their 95% confidence intervals (CI) were used.
Thirteen studies with 4429 patients were included in the meta-analysis. The results showed that VETC was significantly associated with both OS (HR 2.00; 95% CI 1.64-2.45) and TE (HR 1.70; 95% CI 1.44-1.99) in HCC patients. Furthermore, recurrence-free survival (RFS) was a stronger indicator of tumor efficacy (HR 1.73; 95% CI 1.44-2.07) than disease-free survival (DFS) (HR 1.69; 95% CI 1.22-2.35). This suggests that VETC-positive HCC has a higher risk of recurrence and a lower survival rate.
In conclusion, the meta-analysis suggests that VETC is a significant predictor of overall survival and tumor efficacy in HCC patients and may be a valid prognostic indicator.
研究表明，包裹肿瘤簇的血管（VETC）是肝细胞癌（HCC）患者预后的有力预测指标。
在PubMed、Embase、Web of Science和Scopus数据库中进行了系统检索。总生存期（OS）和肿瘤疗效（TE）是用于评估VETC与HCC预后之间关系的两个结局指标。使用风险比（HR）及其95%置信区间（CI）。
荟萃分析纳入了13项研究，共4429例患者。结果显示，VETC与HCC患者的OS（HR 2.00；95%CI 1.64 - 2.45）和TE（HR 1.70；95%CI 1.44 - 1.99）均显著相关。此外，无复发生存期（RFS）比无病生存期（DFS）（HR 1.69；95%CI 1.22 - 2.35）是更强的肿瘤疗效指标（HR 1.73；95%CI 1.44 - 2.07）。这表明VETC阳性的HCC复发风险更高，生存率更低。
总之，荟萃分析表明，VETC是HCC患者总生存期和肿瘤疗效的重要预测指标，可能是一个有效的预后指标。
